- Home
- HRZN vs DBVT Comparison
HRZN vs DBVT Comparison
Compare HRZN & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRZN
- DBVT
- Stock Information
- Founded
- HRZN 2008
- DBVT 2002
- Country
- HRZN United States
- DBVT France
- Employees
- HRZN N/A
- DBVT N/A
- Industry
- HRZN Finance/Investors Services
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HRZN Finance
- DBVT Health Care
- Exchange
- HRZN Nasdaq
- DBVT Nasdaq
- Market Cap
- HRZN 295.3M
- DBVT 260.5M
- IPO Year
- HRZN 2010
- DBVT N/A
- Fundamental
- Price
- HRZN $6.85
- DBVT $9.80
- Analyst Decision
- HRZN Hold
- DBVT Buy
- Analyst Count
- HRZN 4
- DBVT 4
- Target Price
- HRZN $7.81
- DBVT $14.81
- AVG Volume (30 Days)
- HRZN 624.6K
- DBVT 33.9K
- Earning Date
- HRZN 10-28-2025
- DBVT 11-05-2025
- Dividend Yield
- HRZN 19.27%
- DBVT N/A
- EPS Growth
- HRZN N/A
- DBVT N/A
- EPS
- HRZN N/A
- DBVT N/A
- Revenue
- HRZN $97,144,000.00
- DBVT $3,800,000.00
- Revenue This Year
- HRZN $0.51
- DBVT $1,743.46
- Revenue Next Year
- HRZN $9.90
- DBVT $1,045.66
- P/E Ratio
- HRZN N/A
- DBVT N/A
- Revenue Growth
- HRZN N/A
- DBVT N/A
- 52 Week Low
- HRZN $6.77
- DBVT $2.21
- 52 Week High
- HRZN $11.08
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- HRZN 36.75
- DBVT 54.19
- Support Level
- HRZN $6.79
- DBVT $9.58
- Resistance Level
- HRZN $6.97
- DBVT $10.19
- Average True Range (ATR)
- HRZN 0.10
- DBVT 0.53
- MACD
- HRZN 0.02
- DBVT 0.06
- Stochastic Oscillator
- HRZN 19.46
- DBVT 61.39
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.